PYC Therapeutics Ltd
ASX:PYC
PYC Therapeutics Ltd
EPS (Diluted)
PYC Therapeutics Ltd
EPS (Diluted) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | EPS (Diluted) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
PYC Therapeutics Ltd
ASX:PYC
|
EPS (Diluted)
AU$0
|
CAGR 3-Years
-100%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Mesoblast Ltd
ASX:MSB
|
EPS (Diluted)
$0
|
CAGR 3-Years
15%
|
CAGR 5-Years
12%
|
CAGR 10-Years
12%
|
|
|
CSL Ltd
ASX:CSL
|
EPS (Diluted)
$2
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-13%
|
CAGR 10-Years
0%
|
|
|
Race Oncology Ltd
ASX:RAC
|
EPS (Diluted)
AU$0
|
CAGR 3-Years
25%
|
CAGR 5-Years
6%
|
CAGR 10-Years
N/A
|
|
|
Clinuvel Pharmaceuticals Ltd
ASX:CUV
|
EPS (Diluted)
AU$0
|
CAGR 3-Years
9%
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
|
Telix Pharmaceuticals Ltd
ASX:TLX
|
EPS (Diluted)
AU$0
|
CAGR 3-Years
55%
|
CAGR 5-Years
35%
|
CAGR 10-Years
N/A
|
|
PYC Therapeutics Ltd
Glance View
PYC Therapeutics Ltd. is a drug-development company, which offers a new generation of RNA therapeutics to meet unmet need in disease. The company is headquartered in Nedlands, Western Australia. The company went IPO on 2005-03-30. The firm has RNA targeted therapeutics design capabilities to deliver technology based on cell penetrating peptides (CPPs). The firm develops a pipeline of therapies, including three preclinical stage programs, which are focused on inherited eye diseases and preclinical discovery efforts, which are focused on neurodegenerative diseases. The Company’s lead drug candidate, VP-001 is designed to treat Retinitis pigmentosa 11 (RP11). The second lead drug candidate VP-002, which is focused on treating autosomal dominant optic atrophy (ADOA) and PYC-001 drug candidate to treat diabetic retinopathy. Its preclinical, clinical, regulatory and corporate operations are based in San Diego, California. The firm's discovery and laboratory operations are located in Australia.
See Also
What is PYC Therapeutics Ltd's EPS (Diluted)?
EPS (Diluted)
-0.1
AUD
Based on the financial report for Dec 31, 2025, PYC Therapeutics Ltd's EPS (Diluted) amounts to -0.1 AUD.
What is PYC Therapeutics Ltd's EPS (Diluted) growth rate?
EPS (Diluted) CAGR 3Y
-100%
Over the last year, the EPS (Diluted) growth was 27%. The average annual EPS (Diluted) growth rates for PYC Therapeutics Ltd have been -100% over the past three years .
